Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,125 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Influenza Virus Vaccine Clear all
Completed Not applicable Interventional

Vaccine Therapy in Preventing Flu in Children With Acute Lymphoblastic Leukemia

NCT00022035
View directory record Official record
Conditions
Infection, Leukemia
Interventions
trivalent influenza vaccine
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
1 Year to 20 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Hackensack, New Jersey • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 18, 2026, 8:56 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age

NCT02242643
View directory record Official record
Conditions
Influenza
Interventions
FluLaval™ Quadrivalent, Fluzone® Quadrivalent
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 35 Months
Enrollment
2,432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
64
States / cities
Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 18, 2026, 8:56 AM EDT
Not listed Phase 1 Interventional

Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)

NCT04629105
View directory record Official record
Conditions
ARDS, Human, Covid19
Interventions
Longeveron Mesenchymal Stem Cells (LMSCs), Placebo
Biological · Other
Lead sponsor
Longeveron Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Miami, Florida • Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 18, 2026, 8:56 AM EDT
Not yet recruiting Phase 4 Interventional

The INTERvening for LUNG Health Trial

NCT07540000
View directory record Official record
Conditions
Spirometry
Interventions
Community health worker-delivered multi-component respiratory health intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
9 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 18, 2026, 8:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot Study

NCT01090557
View directory record Official record
Conditions
RSV Infection, Bronchiolitis
Interventions
Collection of exhaled breath
Other
Lead sponsor
Winthrop University Hospital
Other
Eligibility
1 Day to 4 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2010 · Synced Oct 18, 2026, 8:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pandemic Influenza Plasmid DNA Vaccines (Needle)

NCT00709800
View directory record Official record
Conditions
Influenza
Interventions
VCL-IPT1, VCL-IPM1, PBS
Biological
Lead sponsor
Vical
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
3
States / cities
San Diego, California • Baltimore, Maryland • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2009 · Synced Oct 18, 2026, 8:56 AM EDT
Active, not recruiting Phase 4 Interventional

Flu Vaccine Responses in the Setting of Melanoma Treatment

NCT03315975
View directory record Official record
Conditions
Viral Vaccines
Interventions
Inactivated influenza vaccine
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 18, 2026, 8:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults

NCT00985673
View directory record Official record
Conditions
Influenza
Interventions
GSK2340274A, GSK2340273A, Seasonal trivalent influenza vaccine (TIV), Saline placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 40 Years
Enrollment
611 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
4
States / cities
Stockbridge, Georgia • Raleigh, North Carolina • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 18, 2026, 8:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

NCT01942265
View directory record Official record
Conditions
Influenza
Interventions
AS03, MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 64 Years
Enrollment
980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
5
States / cities
Baltimore, Maryland • St Louis, Missouri • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 18, 2026, 8:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

NCT03682120
View directory record Official record
Conditions
Avian Influenza, Influenza Immunisation
Interventions
A/H7N9, MF59, Phosphate Buffered Saline (PBS) diluent
Biological · Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • St Louis, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 18, 2026, 8:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effect of Proximity on Flu-Shot Participation

NCT01455753
View directory record Official record
Conditions
Influenza, Human
Interventions
Functional Proximity, Base Proximity
Other
Lead sponsor
National Bureau of Economic Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
1,801 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Oct 18, 2026, 8:56 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age

NCT00885105
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 11 Months
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
6
States / cities
Little Rock, Arkansas • Marietta, Georgia • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 18, 2026, 8:56 AM EDT
Completed No phase listed Observational

Novel Influenza A (H1N1) Surveillance Registry

NCT01046331
View directory record Official record
Conditions
Novel Influenza A, H1N1, Influenza
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
86
States / cities
Anchorage, Alaska • Phoenix, Arizona • Little Rock, Arkansas + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 18, 2026, 8:56 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly

NCT00391053
View directory record Official record
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
High-Dose Inactivated, Split-Virion Influenza Vaccine, Inactivated, Split-Virion Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
3,851 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
28
States / cities
Mesa, Arizona • Phoenix, Arizona • Tempe, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 18, 2026, 8:56 AM EDT
Completed Phase 4 Interventional Results available

Influenza Vaccine Feasibility Study in Children With Persistent Asthma

NCT02967393
View directory record Official record
Conditions
Asthmatic
Interventions
ccIIV4, IIV4
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
5 Years to 11 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Atlanta, Georgia • Durham, North Carolina • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 18, 2026, 8:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A/H5N1/LT Dose Ranging Study

NCT00908687
View directory record Official record
Conditions
Pandemic Influenza
Interventions
A/H5N1, LT Adjuvant Patch
Biological
Lead sponsor
Intercell USA, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
6
States / cities
Anaheim, California • Vallejo, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 18, 2026, 8:56 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old

NCT01992107
View directory record Official record
Conditions
Influenza
Interventions
QIVc, TIV1c, TIV2c
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
4 Years to 18 Years
Enrollment
2,333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
88
States / cities
Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 18, 2026, 8:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults

NCT01427309
View directory record Official record
Conditions
Influenza
Interventions
High Dose Trivalent Inactivated Influenza Vaccine, Trivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
31,989 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
105
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Oct 18, 2026, 8:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Revealing Protective Immunity to Influenza Using Systems Immunology

NCT06501963
View directory record Official record
Conditions
Influenza
Interventions
Live Attenuated Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 18, 2026, 8:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults

NCT00853255
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 18, 2026, 8:56 AM EDT
Terminated No phase listed Observational Results available

Clinical Validation of the Point-of-Care MSD Influenza Test

NCT00863343
View directory record Official record
Conditions
Influenza Human
Interventions
Public Health Notification
Biological
Lead sponsor
Meso Scale Diagnostics, LLC.
Industry
Eligibility
Not listed
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
San Diego, California • Lebanon, New Hampshire • Port Jefferson, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Oct 18, 2026, 8:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

NCT05585632
View directory record Official record
Conditions
SARS-CoV-2, Influenza, RSV
Interventions
mRNA-1010, mRNA-1345, mRNA-1273.214, mRNA-1045, mRNA-1230
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
392 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
14
States / cities
DeLand, Florida • Hollywood, Florida • St. Petersburg, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 18, 2026, 8:56 AM EDT
Terminated Phase 1 Interventional

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT05395052
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
Interventions
FT536, Cyclophosphamide, Fludarabine, IL-2, Avelumab, Pembrolizumab, Nivolumab, Atezolizumab, Trastuzumab, Cetuximab, Amivantamab
Drug · Combination Product
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Scottsdale, Arizona • Los Angeles, California • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 18, 2026, 8:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza

NCT02603952
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, MEDI8852, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
22
States / cities
Canoga Park, California • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 18, 2026, 8:56 AM EDT